Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

Pharmacology Biochemistry and Behavior

Volumn 118, Issue , 2014, Pages 36-45

  Bleickardt, Carina J ^a   Kazdoba, Tatiana M ^a   Jones, Nicholas T ^a   Hunter, John C ^a   Hodgson, Robert A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A2A antagonist; Akathisia; EPS; Non human primate; PDE10A inhibitor; SCH 412348

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ARIPIPRAZOLE; HALOPERIDOL; SCH 412348; UNCLASSIFIED DRUG; (7-(2-(4-DIFLUOROPHENYL)-1-PIPERAZINYL)ETHYL)-2-(2-FURANYL)-7H-PYRAZOLO(4,3-E)(1,2,4)TRIAZOLO(1,5-C)PYRIMIDIN-5-AMINE; (7 (2 (4 DIFLUOROPHENYL) 1 PIPERAZINYL)ETHYL) 2 (2 FURANYL) 7H PYRAZOLO(4,3 E)(1,2,4)TRIAZOLO(1,5 C)PYRIMIDIN 5 AMINE; 2 ((4 (1 METHYL 4 PYRIDIN 4 YL 1H PYRAZOL 3 YL)PHENOXY)METHYL)QUINOLINE; 2-((4-(1-METHYL-4-PYRIDIN-4-YL-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE; ADENOSINE A2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TRIAZOLE DERIVATIVE;

AKATHISIA; AKATHISIA LIKE BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BARNES AKATHISIA SCALE; BRUXISM; CEBUS APELLA; FEMALE; HILLSIDE AKATHISIA SCALE; LIMB MOVEMENT; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; VOCALIZATION; A(2A) ANTAGONIST; ANIMAL; ANIMAL BEHAVIOR; CEBUS; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EPS; HUMAN; MOTOR ACTIVITY; NON-HUMAN PRIMATE; PATHOPHYSIOLOGY; PDE10A INHIBITOR; PSYCHOLOGICAL ASPECT;

A(2A) ANTAGONIST; AKATHISIA; EPS; NON-HUMAN PRIMATE; PDE10A INHIBITOR; SCH 412348;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AKATHISIA, DRUG-INDUCED; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CEBUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; MALE; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PYRAZOLES; PYRIMIDINES; QUINOLINES; QUINOLONES; TRIAZOLES;

EID: 84893175136     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.10.030     Document Type: Article

References (67)

1. W. Alderton, E. Karran, and S. Ward Current and future perspectives in psychiatric drug discovery Drug News Perspect 22 2009 360 364
2. A.L. Auclair, M.S. Kleven, J. Besnard, R. Depoortère, and A. Newman-Tancredi Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade Neuropsychopharmacology 31 2006 1900 1909
3. C.F. Baldassano, C.J. Truman, A. Nierenberg, S.N. Ghaemi, and G.S. Sachs Akathisia: a review and case report following paroxetine treatment Compr Psychiatry 37 1996 122 124
4. T.R.E. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
5. T.R.E. Barnes The Barnes akathisia rating scale - revisited J Psychopharmacol 17 2003 365 370
6. T.R.E. Barnes, and W.M. Braude Akathisia variants and tardive dyskinesia Arch Gen Psychiatry 42 1985 874 878
7. 2 receptor blocking agent Curr Ther Res 40 1986 492 499
8. A.J. Betz, R. Vontell, J. Valenta, L. Worden, K.S. Sink, and L. Font et al. Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide Neuroscience 163 2009 97 108
9. M. Bishnoi, K. Chopra, and S.K. Kulkarni Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioral, biochemical and neurochemical changes Eur J Pharmacol 552 2006 55 66
10. M. Bishnoi, K. Chopra, and S.K. Kulkarni Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia Pharmacol Rep 59 2007 181 191
11. S. Boyce, C.E. Clarke, R. Luquin, D. Peggs, R.G. Robertson, and I.J. Mitchell et al. Induction of chorea and dystonia in parkinsonian primates Mov Disord 5 1990 3 7
12. W.M. Braude, T.R.E. Barnes, and S.M. Gore Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions Br J Psychiatry 143 1983 139 150
13. J. Bruhwyler, E. Chleide, G. Houbeau, N. Waegeneer, and M. Mercier Differentiation of haloperidol and clozapine using a complex operant schedule in the dog Pharmacol Biochem Behav 44 1993 181 189
14. V. Bubeníková, M. Votava, J. Horácek, T. Pálenícek, and C. Dockery The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating Pharmacol Biochem Behav 80 2005 591 596
15. D.E. Casey Behavioral effects of long-term neuroleptic treatment in Cebus monkeys Psychopharmacology Suppl 2 1985 211 216
16. J. Claghorn, G. Honigfeld, F.S. Abuzzahab Sr., R. Wang, R. Steinbook, and V. Tuason et al. The risks and benefits of clozapine vs chlorpromazine J Clin Psychopharmacol 7 1987 377 384
17. 1 receptors J Pharmacol Exp Ther 249 1989 769 774
18. L.E. Collins, T.N. Sager, A.G. Sams, A. Pennarola, R.G. Port, and M. Shahriari et al. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade Pharmacol Biochem Behav 100 2012 498 505
19. M. Correa, A. Wisniecki, A. Betz, D.R. Dobson, M.F. O'Neill, and M.J. O'Neill et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism Behav Brain Res 148 2004 47 54
20. 2 receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling Brain Res 1476 2012 96 107
21. S. Ferré, G. von Euler, B. Johansson, B.B. Fredholm, and K. Fuxe Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes Proc Natl Acad Sci U S A 88 1991 7238 7241
22. W.W. Fleischhacker, K.J. Bergmann, R. Perovich, L.K. Pestreich, M. Borenstein, and J.A. Lieberman et al. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia Psychopharmacol Bull 25 1989 222 226
23. W.W. Fleischhacker, S.D. Roth, and J.M. Kane The pharmacologic treatment of neuroleptic induced akathisia J Clin Psychopharmacol 10 1990 12 21
24. K. Fuxe, L.F. Agnati, K. Jacobsen, J. Hillion, M. Canals, and M. Torvinen et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease Neurology 61 2003 S19 S23
25. K. Fuxe, D. Marcellino, D.O. Borroto-Escuela, M. Guescini, V. Fernández-Dueñas, and S. Tanganelli et al. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders CNS Neurosci Ther 16 2010 18 42
26. G. Gardos, J.O. Cole, and C. Sniffin An evaluation of papaverine in tardive dyskinesia J Clin Pharmacol 16 1976 304 310
27. G. Gardos, R.P. Granacher, J.O. Cole, and C. Sniffin The effects of papaverine in tardive dyskinesia Prog Neuropsychopharmacol 3 1979 543 550
28. S.M. Grauer, V.L. Pulito, R.L. Navarra, M. Kelly, C. Kelley, and R. Graf et al. PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia J Pharmacol Exp Ther 331 2009 574 590
29. D. Healy Psychiatric drugs explained 2008 Elsevier Health Sciences New York
30. A.H. Heck, P.M. Haffmans, I.W. de Groot, and E. Hoencamp Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial Schizophr Res 46 2000 97 105
31. G.D. Ho, S.W. Yang, J. Smotryski, A. Bercovici, T. Nechuta, and E.M. Smith et al. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of schizophrenia Bioorg Med Chem Lett 22 2012 1019 1022
32. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, and S. Fredduzzi et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression J Pharmacol Exp Ther 330 2009 294 303
33. D.C. Hoffman, and H. Donovan Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability Psychopharmacology (Berl) 120 1995 128 133
34. K. Ishiwari, L.J. Madson, A.M. Farrar, S.M. Mingote, J.P. Valenta, and M.D. DiGianvittorio et al. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats Behav Brain Res 178 2007 190 199
35. P. Jenner, A. Mori, R. Hauser, M. Morelli, B.B. Fredholm, and J.F. Chen Adenosine, adenosine A2A antagonists, and Parkinson's disease Parkinsonism Relat Disord 15 2009 406 413
36. C.K. Jones, M. Bubser, A.D. Thompson, J.W. Dickerson, N. Turle-Lorenzo, and M. Amalric et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with l-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease J Pharmacol Exp Ther 340 2012 404 421
37. J.M. Kane, W.W. Fleischhacker, L. Hansen, R. Perlis, A. Pikalov, and S. Assunção-Talbott Akathisia: an updated review focusing on second-generation antipsychotics J Clin Psychiatry 70 2009 627 643
38. 2A antagonist, blocks haloperidol- and risperidone-induced extrapyramidal syndrome in haloperidol-sensitized Cebus apella non-human primates. Program No. 892.6 2007 Society for Neuroscience San Diego, CA
39. V.A. Keith, R.S. Mansbach, and M.A. Geyer Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle Biol Psychiatry 30 1991 557 566
40. J.H. Kim, and H.J. Byun Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects Clin Neuropharmacol 26 2003 312 316
41. W.A. Kinghorn, and J.P. McEvoy Aripiprazole: pharmacology, efficacy, safety and tolerability Expert Rev Neurother 5 2005 297 307
42. B. Kovacic, and E.F. Domino A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD J Clin Psychopharmacol 2 1982 305 307
43. J.F. Lipinski, G. Mallya, P. Zimmermann, and H.G. Pope Fluoxetine induced akathisia: clinical and theoretical implications J Clin Psychopharmacol 50 1989 339 342
44. H. Lublin, J. Gerlach, and F. Morkeberg Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists Psychopharmacology (Berl) 114 1994 495 504
45. M.S. Malamas, Y. Ni, J. Erdei, H. Stange, R. Schindler, and H.J. Lankau et al. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors J Med Chem 54 2011 7621 7638
46. J. Mally, and T.W. Stone The effect of theophylline on parkinsonian symptoms J Pharm Pharmacol 46 1994 515 517
47. C.D. Marsden, and P. Jenner The pathophysiology of extrapyramidal side-effects of neuroleptic drugs Psychol Med 10 1980 55 72
48. W.T. McElroy, Z. Tan, K. Basu, S.W. Yang, J. Smotryski, and G.D. Ho et al. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound Bioorg Med Chem Lett 22 2012 1335 1339
49. F.S. Menniti, T.A. Chappie, J.M. Humphrey, and C.J. Schmidt Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia Curr Opin Investig Drugs 8 2007 54 59
50. C.H. Miller, W.W. Fleischhacker, H. Ehrmann, and J.M. Kane Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin Psychopharmacol Bull 26 1990 373 376
51. S.G. Potkin, A.R. Saha, M.J. Kujawa, W.H. Carson, M. Ali, and E. Stock et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 2003 681 690
52. J.S. Rodefer, E.R. Murphy, and M.G. Baxter PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats Eur J Neurosci 21 2005 1070 1076
53. P. Sachdev The epidemiology of drug-induced akathisia: Part I. Acute akathisia Schizophr Bull 21 1995 431 449
54. P. Sachdev The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias Schizophr Bull 21 1995 451 461
55. P.S. Sachdev, and M. Brüne Animal models of acute drug-induced akathisia - a review Neurosci Biobehav Rev 24 2000 269 277
56. J.D. Salamone, A.J. Betz, K. Ishiwari, J. Felsted, L. Madson, and B. Mirante et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism Front Biosci 13 2008 3594 3605
57. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, M.L. Corman, M. Hajos, and J.F. Harms et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J Pharmacol Exp Ther 325 2008 681 690
58. E.C. Settle Akathisia and sertraline J Clin Psychiatry 54 1993 321
59. J.A. Siuciak, D.S. Chapin, J.F. Harms, L.A. Lebel, S.A. McCarthy, and L. Chambers et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 51 2006 386 396
60. J.M. Smith, J.M. Uslaner, C.D. Cox, S.L. Huszar, C.E. Cannon, and J.D. Vardigan et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey Neuropharmacology 64 2013 215 223
61. S.M. Stahl Akathisia and tardive dyskinesia Arch Gen Psychiatry 42 1985 915 917
62. T. van Putten Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31 1974 67 72
63. T. van Putten The many faces of akathisia Compr Psychiatry 16 1975 43 47
64. T. van Putten, P.R.A. May, and S.R. Marder Akathisia with haloperidol and thiothixene Arch Gen Psychiatry 41 1984 1036 1039
65. G.B. Varty, R.A. Hodgson, A.J. Pond, M.E. Grzelak, E.M. Parker, and J.C. Hunter The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates Psychopharmacology (Berl) 200 2008 393 401
66. M. Weber, M. Breier, D. Ko, N. Thangaraj, D.E. Marzan, and N.R. Swerdlow Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine Psychopharmacology (Berl) 203 2009 723 735
67. S.W. Yang, J. Smotryski, W.T. McElroy, Z. Tan, G. Ho, and D. Tulshian et al. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia Bioorg Med Chem Lett 22 2012 235 239